Carregant...
Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC)
INTRODUCTION: PDAC is a lethal malignancy with a clear unmet need; almost all patients fail 1(st), 2(nd), and 3(rd) line multi-agent cytotoxic chemotherapy. The mammalian target of rapamycin (mTOR) has been identified as a key signaling node enhancing tumor survival and drug resistance in PDAC, henc...
Guardat en:
| Publicat a: | Expert Opin Investig Drugs |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6681663/ https://ncbi.nlm.nih.gov/pubmed/31215251 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543784.2019.1632289 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|